EMA panel recommends nirogacestat for desmoid tumors

The European Medicines Agency's CHMP recommended approval of SpringWorks Therapeutics' nirogacestat for progressing desmoid tumors in adults, potentially making it the first authorized therapy for this condition in the EU; this recommendation, based on Phase 3 trial data showing a 71% reduction in disease progression risk, follows the drug's prior approval in the United States and has contributed to SpringWorks' 730% revenue growth over the last year. Separately, SpringWorks is progressing with its merger with Merck KGaA, pending shareholder approval, while analysts at H.C. Wainwright maintain a Buy rating with a $74 price target and TD Cowen downgraded the stock to Hold with a $47 target due to the pending acquisition.

Analysis

SpringWorks Therapeutics (NASDAQ:SWTX), a $3.5 billion market cap biotech, has received a significant positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending approval for nirogacestat to treat adults with progressing desmoid tumors. This recommendation, based on Phase 3 DeFi trial results showing a 71% reduction in disease progression risk and improved patient-reported outcomes, positions nirogacestat to potentially become the first authorized therapy for this rare condition in the European Union, where an estimated 1,300-2,300 new cases are diagnosed annually. The European Commission's final decision is anticipated in Q3 2025. This development, alongside nirogacestat's existing U.S. approval, has contributed to SpringWorks' reported 730% revenue growth over the last twelve months and supports its strong financial profile, including 93% gross profit margins and more cash than debt. Concurrently, SpringWorks is progressing with its merger with Merck KGaA, having obtained regulatory clearances and now awaiting shareholder approval, with finalization expected in the second half of 2025. The company also saw a CHMP recommendation for conditional marketing authorization for mirdametinib. Analyst perspectives vary: H.C. Wainwright maintains a Buy rating and a $74 price target, citing nirogacestat's European potential, while TD Cowen downgraded SWTX to Hold with a $47 price target, primarily due to the pending acquisition by Merck KGaA, which they view as strategically beneficial for the acquirer. The stock has demonstrated strong recent performance, gaining 31% over the past six months.

Key Decisions for Investors

• Investors should evaluate the intrinsic value derived from SpringWorks' pipeline advancements, particularly nirogacestat's potential EU market entry and mirdametinib's progress, against the constraints of the pending acquisition by Merck KGaA, which could cap upside potential as reflected in TD Cowen's $47 price target.
• Key catalysts to monitor include the European Commission's final decision on nirogacestat in Q3 2025 and the shareholder vote regarding the Merck KGaA merger, as these events will critically influence the stock's trajectory and the realization of its current 31% six-month gain.
• Consider the differing analyst outlooks, with H.C. Wainwright's $74 target possibly reflecting standalone or synergistic value beyond the immediate acquisition terms, and align investment strategy with individual risk assessment regarding the merger's completion and terms.